Thus far, several attempts using CART cells against CSCs have been tested in several types of solid tumors in animal models, including anti-CD133 CART cells in treating glioblastoma, and anti-EpCAM CART cells for prostate cancer and peritoneal carcinomatosis from gastrointestinal and gynecologic malignancies (Zhu et al., 2015; Deng et al., 2015; Ang et al., 2017). Here, EPCAM is linked to prostate cancer.